Literature DB >> 19958590

Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats.

Atish Kumar Prakash1, Anil Kumar.   

Abstract

OBJECTIVES: Oxidative stress is emerging as an important issue in the pathogenesis of dementia. This study was conducted to investigate the possible neuroprotective effects of carvedilol against streptozotocin induced behavioural alterations and oxidative damage in rats.
METHODS: An intracerbroventricular cannula was implanted in the lateral ventricles of male Wistar rats. Various behavioural (locomotor activity, Morris water maze task) and biochemical parameters (lipid peroxidation, nitrate concentration, catalase, acetylcholinesterase, reduced glutathione and protein) were assessed. KEY
FINDINGS: Intracerebroventricular administration of streptozotocin caused a significant memory deficit as evaluated in the Morris water maze task paradigms, and caused marked oxidative damage as indicated by significant increases in malondialdehyde and nitrite levels, and depletion of superoxide dismutase, catalase and reduced glutathione levels. It also caused a significant increase in acetylcholinesterase activity. Chronic administration of carvedilol (1 and 2 mg/kg, i.p.) for a period of 25 days starting 4 days before streptozotocin administration resulted in an improvement in memory retention, and attenuation of oxidative damage and acetylcholinesterase activity.
CONCLUSIONS: This study demonstrates the effectiveness of carvedilol in preventing cognitive deficits as well as the oxidative stress caused by intracerbroventicular administration of streptozotocin in rats. Carvedilol may have potential in the treatment of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958590     DOI: 10.1211/jpp/61.12.0012

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30.

Authors:  E Sofic; M Salkovic-Petrisic; I Tahirovic; A Sapcanin; S Mandel; M Youdim; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2014-09-25       Impact factor: 3.575

2.  Modulation of the Nitrergic Pathway via Activation of PPAR-γ Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction.

Authors:  Atish Prakash; Anil Kumar; Long Chiau Ming; Vasudevan Mani; Abu Bakar Abdul Majeed
Journal:  J Mol Neurosci       Date:  2015-02-18       Impact factor: 3.444

3.  Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress.

Authors:  Caren Nádia Soares de Sousa; Ingridy da Silva Medeiros; Germana Silva Vasconcelos; Gabriel Angelo de Aquino; Francisco Maurício Sales Cysne Filho; Jamily Cunha de Almeida Cysne; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Psychopharmacology (Berl)       Date:  2022-01-13       Impact factor: 4.530

Review 4.  What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research.

Authors:  Melita Salkovic-Petrisic; Ana Knezovic; Siegfried Hoyer; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-08-12       Impact factor: 3.575

5.  Oxidative stress induced by the Fe/ascorbic acid system or model ischemia in vitro: effect of carvedilol and pyridoindole antioxidant SMe1EC2 in young and adult rat brain tissue.

Authors:  Zdenka Gáspárová; Olga Ondrejičková; Alena Gajdošíková; Andrej Gajdošík; Vladimír Snirc; Svorad Stolc
Journal:  Interdiscip Toxicol       Date:  2010-12

6.  In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin.

Authors:  Audrey Kraska; Mathieu D Santin; Olène Dorieux; Nelly Joseph-Mathurin; Emmanuel Bourrin; Fanny Petit; Caroline Jan; Marion Chaigneau; Philippe Hantraye; Pierre Lestage; Marc Dhenain
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.